ASCO 2025 | The CAR T Vision project: doubling the number of patients receiving CAR T-cell therapy by 2030
Currently, only approximately 20-25% of patients with hematological malignancies who are eligible for CAR T-cell therapy receive this treatment. In this interview, Jason Westin, MD, MS, FACP, FASCO, The University of Texas MD Anderson Cancer Center, Houston, TX, introduces the CAR T Vision project—a collaborative effort aimed at doubling the number of patients receiving CAR T-cell therapy by 2030. Prof. Westin emphasizes the importance of bringing together relevant stakeholders, including physicians, patient advocates, payers, and hospital organizations, to achieve this ambitious goal. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Hi, I’m Dr Jason Weston and I’m thrilled to be here at the ASCO 2025 meeting where we’re talking about many new advances, but one of the key things I wanted to highlight was the CAR T-cell vision project.
CAR T-cell is a breakthrough new therapy. It’s been approved in many hematologic indications for about seven or eight years...
Hi, I’m Dr Jason Weston and I’m thrilled to be here at the ASCO 2025 meeting where we’re talking about many new advances, but one of the key things I wanted to highlight was the CAR T-cell vision project.
CAR T-cell is a breakthrough new therapy. It’s been approved in many hematologic indications for about seven or eight years. However, unfortunately, despite it being a curative therapy, only about 20-25% of people who should get it are currently getting it.
CAR T-cell vision is a program working with all the relevant stakeholders, trying to get them on the same page, trying to get them all together to work on the problem as a whole group as opposed to individual components. The CAR-T Vision Project is bringing stakeholders together including physicians, patient advocates, payers, hospital organizations, all the relevant groups with the single goal of trying to double the number of patients who get CAR-T cell therapy by the year 2030. The goal is achievable, it’s bold, but the aim to try and help more people with what we think is one of the best treatment options for some certain cancers is doable if we work together as a group. And so success would look like growing the number of people getting CAR T-cells, but we want to aim high and we want to double that number within the next five years.
So one thing I’d like viewers to take away from this interview is that the CAR T-cell Vision Project is a living document. This is something that we encourage those that are listening to learn more by visiting the CAR-T Vision website or seeing us on LinkedIn. On the website or on any of the platforms, there is a white paper from the steering committee group which I was privileged to serve on, where we outline the problems, the stakeholders, some potential solutions and call to action for others to get engaged. So if you’re watching this and curious about CAR T-cells, a way that you could help solve this problem would be to visit the CAR T-cell vision website and learn more at that site.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
